Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) FCF Margin (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed FCF Margin for 4 consecutive years, with 171.27% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin fell 9815.0% to 171.27% in Q3 2025 year-over-year; TTM through Sep 2025 was 125.53%, a 4793.0% decrease, with the full-year FY2024 number at 78.44%, up 16087.0% from a year prior.
  • FCF Margin was 171.27% for Q3 2025 at bioAffinity Technologies, up from 209.58% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 94.21% in Q2 2022 to a low of 169528.23% in Q1 2023.
  • A 4-year average of 27586.28% and a median of 135.24% in 2024 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -700377bps in 2023, then skyrocketed 16942902bps in 2024.
  • bioAffinity Technologies' FCF Margin stood at 55440.58% in 2022, then soared by 100bps to 72.42% in 2023, then fell by -5bps to 75.97% in 2024, then crashed by -125bps to 171.27% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's FCF Margin are 171.27% (Q3 2025), 209.58% (Q2 2025), and 91.31% (Q1 2025).